SCHEMBL560838

SCHEMBL560838

CCOC(=O)C(CC(=O)OCc1ccccc1)(NC(=O)OC(C)(C)C)C(=O)OCC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
RECQL P46063 1/20 0.51
SYK P43405 1/20 0.49
PTPRB P23467 2/20 0.48
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
ACP1 P24666 1/20 0.48
MMP8 P22894 1/20 0.45
AKT1 P31749 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA7 P43166 1/20 0.41
CA14 Q9ULX7 1/20 0.41
PPARA Q07869 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560684 0.95 ALDH1A1 (0.49) ALDH1A1RECQLSYKPTPRBPTPN2
SCHEMBL560683 0.95 ALDH1A1 (0.49) ALDH1A1RECQLSYKPTPRBPTPN2
SCHEMBL560930 0.93 ALDH1A1 (0.47) ALDH1A1RECQLSYKPTPRBPTPN2
SCHEMBL560931 0.93 ALDH1A1 (0.47) ALDH1A1RECQLSYKPTPRBPTPN2
SCHEMBL561264 0.92 PTPRB (0.53) ALDH1A1RECQLSYKPTPRBPTPN2
SCHEMBL560612 0.91 PTPN2 (0.56) ALDH1A1RECQLSYKPTPRBPTPN2
SCHEMBL560509 0.89 PTPN2 (0.56) ALDH1A1RECQLSYKPTPRBPTPN2
SCHEMBL560866 0.85 PTPN2 (0.58) ALDH1A1RECQLSYKPTPRBPTPN2
SCHEMBL560507 0.84 PTPN2 (0.54) ALDH1A1RECQLSYKPTPRBPTPN2
SCHEMBL560508 0.84 PTPN2 (0.54) ALDH1A1RECQLSYKPTPRBPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434737-B2 Process for producing optically active succinimide derivatives and intermediates thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2016-09-06 US disclosed
US-20140099681-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF KYOWA HAKKO BIO CO., LTD. (JP) 2014-04-10 US disclosed
US-8633001-B2 Process for producing optically active succinimide derivatives and intermediates thereof DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-01-21 US disclosed
US-20120034660-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF KYOWA HAKKO BIO CO., LTD. (JP) 2012-02-09 US disclosed
EP-2395097-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVE AND INTERMEDIATE THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140099681-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF SDHA, STS, DHPS ALDH1A1 255/4885RECQL 3355/4885SYK 1730/4885
US-20120034660-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF SDHA, STS, ALDH18A1 ALDH1A1 265/4885RECQL 3614/4885SYK 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.